To highlight the pressing issues in myeloma clinical trial access and quality of life (QoL) measurements, Myeloma Patients Europe (MPE) is sharing two key reports.
Addressing access barriers in Central and Eastern Europe (CEE):
Our research on “Addressing Access Barriers to Myeloma Clinical Trials in CEE” revealed disparities in trial availability and patient participation.
Key findings include:
- Only 6% of global myeloma trials included CEE countries.
- 11 of 17 CEE countries with trials are EU members.
- Countries like the Czech Republic, Poland and Russia lead in trial numbers, while many others have minimal to no access.
- EU membership, funding and infrastructure are crucial factors.
- The report offers 27 recommendations to improve access, including regional collaboration, policy enhancements and better patient communication.
Quality of Life (QoL) data in myeloma trials (2011-2021):
Our analysis of Quality of Life(QoL) data from myeloma trials underscores the importance of capturing patient-reported outcomes (PROs) to fully understand the impact of treatments on patients’ daily lives. Despite the improvements in myeloma survival rates, QoL measures are crucial for:
- Enhancing patient experience and prognosis.
- Supporting regulatory and reimbursement decisions.
- Informing patient decision-making.
- The report offers insights into current practices and emphasises the need for consistent QoL measurement.
Together, these reports shed light on the challenges of trial access and the importance of QoL data, advocating for better support and improvements for myeloma patients across Europe.
